Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 3Phase 3 2Phase 1 2

Status

Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 37Lymphoma, Follicular 22Lymphoma, Mantle-Cell 18Lymphoma, Large B-Cell, Diffuse 14Lymphoma, B-Cell, Marginal Zone 11Lymphoma, Non-Hodgkin 10Lymphoma 6Neoplasms 4Lymphoma, B-Cell 4Leukemia 3Waldenstrom Macroglobulinemia 2Neoplasm, Residual 2Leukemia, Hairy Cell 2Leukemia, B-Cell 2Dendritic Cell Sarcoma, Interdigitating 2Recurrence 1Oncology Patients Receiving Chemotherapy 1Neoplasm Metastasis 1Lymphoproliferative Disorders 1Indolent Non-Hodgkin's Lymphoma 1Indolent Non-Hodgkin Lymphoma 1Disease 1Cytokine Release Syndrome 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × obinutuzumab × Clear all
NCT03322865 2026-05-06

Obinutuzumab in Marginal Zone Lymphoma

University of Ulm

Phase 2 Active not recruiting
56 enrolled
Lymphoid

Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT06108232 2026-04-07

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
33 enrolled
Lymphoid

Lymphoma, Follicular, Neoplasms

NCT04895436 2026-02-09

ReVenG

AbbVie

Phase 2 Recruiting
75 enrolled
LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02371590 2018-02-23

Lenalidomide and Obinutuzumab for Previously Untreated CLL

University of California, San Diego

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡